文献速递消化系统肿瘤

基于基因型选择晚期结直肠癌治疗的SETICC随机II期药物遗传学研究

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
PubMed 文献 · Ann Oncol · 2018-01-01

SETICC是一项随机开放标签II期试验,比较贝伐珠单抗联合XELOX(对照)与根据TYMS-3'UTR 6 bp ins/del和ERCC1-118C/T多态性定制治疗(实验组)在mCRC患者中的疗效。共195例患者随机分组(对照65例,实验130例)。主要终点PFS未达优效(9.4 vs 10.1个月,P=0.745),但实验组ORR(65% vs 47%,P=0.042)和R0切除率(86% vs 44%,P=0.018)显著提高,且神经毒性等不良事件更少。

要点

  • 基于TYMS-3'UTR和ERCC1-118多态性定制治疗未改善mCRC患者PFS和OS。
  • 实验组客观缓解率(65% vs 47%,P=0.042)和R0切除率(86% vs 44%,P=0.018)显著优于对照。
  • 实验组神经病变、手足综合征、血小板减少和感觉异常显著更少。

核心结论

  • 基于TYMS-3'UTR和ERCC1-118多态性的治疗定制未在mCRC中显示生存获益,但提高了ORR和R0切除率并减少了致残性毒性。

研究设计与样本

  • 随机、开放标签II期试验,比较贝伐珠单抗联合XELOX(对照)与根据TYMS-3'UTR 6 bp ins/del和ERCC1-118C/T多态性定制治疗(实验组),共随机195例患者(对照65例,实验130例),主要终点为PFS。

主要发现

  • 中位PFS:对照组9.4个月,实验组10.1个月(P=0.745),主要终点未达到。
  • 中位OS:对照组16.5个月,实验组19.1个月(P=0.797),两组相似。
  • ORR:实验组65%,对照组47%(P=0.042)。
  • R0切除率:实验组86%,对照组44%(P=0.018)。
  • 实验组神经病变、手足综合征、血小板减少和感觉异常显著更少。

关键数值与推荐

  • 有利多态性组合为TYMS-3'UTR ins/del或del/del且ERCC1-118T/T,据此选择FUOX、FUIRI、XELIRI或XELOX方案。

临床怎么用

  • 对于mCRC患者,基于TYMS-3'UTR和ERCC1-118多态性定制治疗虽未改善生存,但可提高缓解率和R0切除率并减少致残性毒性,值得进一步研究。

局限性

  • 本研究为II期试验,样本量有限,主要终点未达到,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There has been little progress toward personalized therapy for patients with metastatic colorectal cancer (mCRC). TYMS-3' untranslated region (UTR) 6 bp ins/del and ERCC1-118C/T polymorphisms were previously reported to facilitate selecting patients for fluoropyrimidine-based treatment in combination with oxaliplatin as first-line therapy. We assessed the utility of these markers in selecting therapy for patients with mCRC. PATIENTS AND METHODS: This randomized, open-label phase II trial compared bevacizumab plus XELOX (control) versus treatment tailored according to TYMS-3'UTR 6 bp ins/del and ERCC1-118C/T polymorphisms. Patients randomized to the experimental treatment received bevacizumab plus FUOX, FUIRI, XELIRI, or XELOX depending on their combination of favorable polymorphisms for FUOX treatment (TYMS-3'UTR ins/del or del/del; ERCC1-118T/T). Progression-free survival (PFS) was the primary end point. RESULTS: Overall, 195 patients were randomized (control n = 65; experimental n = 130). The primary objective was not met: median PFS was 9.4 months in the control group and 10.1 months in the experimental group (P = 0.745). Median overall survival was similar in both groups (16.5 versus 19.1 months, respectively; P = 0.797). Patients in the experimental group had a significantly higher overall response rate (ORR; 65% versus 47% in the control group; P = 0.042) and R0 resection rate (86% versus 44%, respectively; P = 0.018). Neuropathy, hand-foot syndrome, thrombocytopenia, and dysesthesia were significantly less common in the experimental group. CONCLUSIONS: This study did not show survival benefits after treatment personalization based on polymorphisms in mCRC. However, the improved ORR and R0 resection rate and fewer disabling toxicities suggest that tailoring therapy by TYMS-3'UTR and ERCC1-118 polymorphisms warrants further investigation in patients with mCRC. CLINICALTRIALS.GOV: NCT01071655.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Abad A, Martínez-Balibrea E, Viéitez JM, et al. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. Ann Oncol. 2018. PMID: 29145602. doi:10.1093/annonc/mdx737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。